Influence of gut bile acid composition on the glucose‐lowering effect and safety of metformin
British Journal of Clinical Pharmacology · 2025
DOI: 10.1111/bcp.16358 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Deok Yong Yoon und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South Korea. Hauptthemen laut MEDLINE: Metformin, Cholestyramine Resin, Bile Acids and Salts, Hypoglycemic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: SNUBH Research Fund.
Abstract (Originalsprache)
Aims
This study evaluates how changes in intestinal bile acid composition, induced by cholestyramine, a bile acid sequestrant, affect metformin's pharmacodynamics (PD).
Methods
An open‐label, 2‐period 1‐sequence crossover study was conducted with healthy male adults. Each period consisted of both before and after metformin treatments. Cholestyramine was administered during the second period to change the bile acid pool. For, PD assessment, an oral glucose tolerance test was conducted at each treatment in both periods. Metformin was administered 3 times during each period, and cholestyramine was administered 3 times per day for 7 days during the second period. Maximum serum glucose concentration, area under the glucose concentration curve and homeostatic model assessment of insulin resistance were calculated. Baseline‐corrected PD parameters were derived by subtracting pre‐metformin values from post‐metformin values. Lipid and panels and bile acid profiles in stool were measured. Adverse events were monitored throughout the study.
Results
Fourteen subjects completed the study. The mean values of 3 PD parameters were all decreased after metformin administration in both periods. Cholestyramine administration led to a further decrease in baseline‐corrected PD parameters, significantly reducing the area under the glucose concentration curve by 44.7%. Diarrhoea, the most common adverse event, was reported in 10 subjects during the metformin alone treatment and in 1 subject during the cholestyramine combined treatment ( P < .01).
Conclusion
Cholestyramine affected the glucose‐lowering effect of metformin by the possible change in the bile acid pool in the gut, and metformin‐associated diarrhoea was improved by cholestyramine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South Korea.
- Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea.
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam, Republic of Korea.
ORCID-Profile: Deok Yong Yoon, Joo-Youn Cho, Jae-Yong Chung
Förderung
- SNUBH Research Fund
Zitieren
APA
Yoon, D. Y., Kim, J., Cho, J. Y., & Chung, J. Y. (2025). Influence of gut bile acid composition on the glucose‐lowering effect and safety of metformin. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16358
Vancouver
Yoon DY, Kim J, Cho JY, Chung JY. Influence of gut bile acid composition on the glucose‐lowering effect and safety of metformin. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16358
BibTeX
@article{Yoon2025,
author = {Yoon, Deok Yong and Kim, Jungeun and Cho, Joo-Youn and Chung, Jae-Yong},
title = {Influence of gut bile acid composition on the glucose‐lowering effect and safety of metformin},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1111/bcp.16358}
}
EUVIMED